Table 3.
Infection Risk Analysis: Patients With All Serious Infections Versus Those with No Infection
| Parameter | Univariate Comparison | Multivariate Comparison | ||
|---|---|---|---|---|
| OR (95% CI) | P Value | OR (95% CI) | P Value | |
| Age | 1.01 (.98–1.04) | .49 | … | … |
| Female sex | 1.09 (.59–2.01) | .79 | … | … |
| CLL as underlying cancer | 0.87 (.48–1.57) | .64 | ||
| Ibrutinib daily dose | 1.001 (.999–1.003) | .42 | … | … |
| ≥3 Prior treatment regimens | 1.98 (1.09–3.61) | .02 | 2.03 (1.17–3.52) | .01 |
| Concurrent antitumor agents other than ibrutinib | 1.23 (.52–2.93) | .64 | … | … |
| Prior fludarabine | 0.66 (.21–2.15) | .66 | … | … |
| Neutropenia | 3.35 (1.67–6.75) | .001 | 2.78 (1.34–5.76) | .006 |
| Lymphopenia | 2.08 (.81–5.34) | .13 | 2.02 (.84–4.86) | .11 |
| Corticosteroid use | 1.72 (.65–4.50) | .27 | … | … |
| Antimicrobial prophylaxis | ||||
| PJP prophylaxis | 1.95 (.94–4.05) | .074 | 1.30 (.61–2.77) | .49 |
| Antifungal prophylaxis | 1.73 (.42–7.04) | .45 | … | … |
Abbreviations: CI, confidence interval; CLL, chronic lymphocytic leukemia; OR, odds ratio; PJP, Pneumocystis jirovecii pneumonia.